
AbbVie’s Acquisition of Landos Biopharma Bolsters its Reach in Inflammatory and Autoimmune Conditions
AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) have announced a definitive agreement today, wherein AbbVie will acquire Landos, a clinical stage biopharmaceutical company primarily focused…












